Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
DAVIS KEITH L	TOOELE UT

International Classification(s)

• B67D:DISPENSING, DELIVERING, OR TRANSFERRING LIQUIDS, N....

• 2018 Application Filing Year
• B67D Class
• 535 Applications Filed
• 379 Patents Issued To-Date
• 70.85 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Davis, Keith L	Tooele, US	18	609
# of filed Patents : 18 Total Citations : 609

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• B67D Class

• 0 % this patent is cited more than
• 7 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
7.5 Year Payment	$3600.00	$1800.00	$900.00	Mar 13, 2026
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Mar 13, 2030

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2017/0020,835

INOS-INHIBITORY COMPOSITIONS AND THEIR USE AS BREAST CANCER THERAPEUTICS

---

Abstract

---

Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human breast cancer employing one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents, including calcium channel antagonists, either alone, and further in combination with one or more conventional chemotherapeutic or anti-cancer regimens. Also disclosed are particular therapeutic formulations including these compositions, and methods for their use in treating refractory, metastatic, and relapsed cancers, and for managing or reversing treatment resistance in human triple-negative breast cancers in particular.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.